Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.62 - $39.47
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.57M
Market Cap
$6.89B
Enterprise Value$6.74B
Total Cash (Recent Filing)-$92.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Apr 29, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.85
Shares Outstanding189,856,020
10 Day Avg. Volume2,107,073
30 Day Avg. Volume2,568,818
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.80
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit30.90
Enterprise Value/Ebitda-15.42
Forecast
1Y Price Target
$56.77Price Target Upside56.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Commercial PerformanceBridgeBio has seen initial commercial momentum, with 1,028 patient prescriptions written for acoramidis by 516 physicians.
Pricing StrategyPricing strategy favors Attruby, which is priced significantly lower than Amvuttra, providing a competitive advantage.
Regulatory ApprovalsAcoramidis was approved by the FDA as Attruby™, the first and only approved product for adults with ATTR-CM in the United States.
Bears Say
Operational ChallengesDespite challenges, there is a reported lag in getting prescribed patients on therapy.
---
Ownership Overview
29.25% Insiders
16.80% Mutual Funds
0.62% Other Institutional Investors
39.22% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $21.62 and its highest was $39.47 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
BridgeBio Pharma Inc’s market cap is $6.89B.
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Apr 29, 2025 which is in 2 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Feb 20, 2025. The company reported -$1.4 earnings per share for the quarter, missing the consensus estimate of -$1.12 by -$0.28.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -0.92.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 189,856,020 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$1.4 in its last earnings report, missing expectations of -$1.12. Following the earnings report the stock price went up 1.405%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Currently, no hedge funds are holding shares in BBIO
---
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$56.77 (56.39% Upside)
$56.77 (56.39% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $304.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.21%
12-Months-Change
Fundamentals
Return on Equity
35.68%
Trailing 12-Months
Asset Growth
68.26%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
---
BBIO Stock 12 Month Forecast
Average Price Target
$56.77
▲(56.39% Upside)
Technical Analysis
Sarepta Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
Revolution Medicines
―
Legend Biotech
―
Best Analysts Covering BBIO
1 Year
1 Year Success Rate
14/17 ratings generated profit
1 Year Average Return
+27.43%
reiterated a buy rating 5 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 82.35% of your transactions generating a profit, with an average return of +27.43% per trade.
---